Jefferies Group reaffirmed their buy rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research report released on Saturday. They currently have a $93.00 target price on the biopharmaceutical company’s stock.

Several other equities research analysts have also weighed in on GILD. Berenberg Bank started coverage on Gilead Sciences in a report on Thursday, September 22nd. They issued a buy rating for the company. Piper Jaffray Companies set a $108.00 target price on Gilead Sciences and gave the stock a buy rating in a report on Thursday, September 22nd. Leerink Swann set a $112.00 target price on Gilead Sciences and gave the stock a buy rating in a report on Thursday, September 22nd. Gabelli restated a buy rating on shares of Gilead Sciences in a report on Friday, September 23rd. Finally, Bank of America Corporation restated a neutral rating and issued a $100.00 target price on shares of Gilead Sciences in a report on Sunday, September 25th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $96.41.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) opened at 73.07 on Friday. Gilead Sciences has a 12-month low of $70.83 and a 12-month high of $103.10. The firm has a 50-day moving average of $73.96 and a 200-day moving average of $77.97. The firm has a market cap of $96.27 billion, a P/E ratio of 6.76 and a beta of 1.20.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.87 by $0.12. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The company earned $7.40 billion during the quarter, compared to analyst estimates of $7.47 billion. During the same quarter last year, the firm posted $3.22 earnings per share. The firm’s revenue for the quarter was down 9.6% compared to the same quarter last year. On average, analysts expect that Gilead Sciences will post $11.47 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This report was posted by Watch List News and is the propert of of Watch List News. If you are accessing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright laws. The legal version of this report can be read at http://www.watchlistnews.com/jefferies-group-reaffirms-buy-rating-for-gilead-sciences-inc-gild/1061470.html.

The company also recently declared a quarterly dividend, which was paid on Thursday, December 29th. Stockholders of record on Thursday, December 15th were paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 2.57%. The ex-dividend date of this dividend was Tuesday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 17.44%.

In other news, insider John C. Martin sold 73,337 shares of the company’s stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $73.59, for a total transaction of $5,396,869.83. Following the transaction, the insider now owns 3,204,433 shares of the company’s stock, valued at $235,814,224.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John W. Madigan sold 105,000 shares of the company’s stock in a transaction on Friday, November 18th. The shares were sold at an average price of $74.86, for a total value of $7,860,300.00. Following the transaction, the director now directly owns 121,761 shares in the company, valued at approximately $9,115,028.46. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. W.G. Shaheen & Associates DBA Whitney & Co raised its position in shares of Gilead Sciences by 8.5% in the second quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 45,835 shares of the biopharmaceutical company’s stock valued at $3,824,000 after buying an additional 3,610 shares during the period. Bright Rock Capital Management LLC raised its position in shares of Gilead Sciences by 17.3% in the second quarter. Bright Rock Capital Management LLC now owns 88,225 shares of the biopharmaceutical company’s stock valued at $7,360,000 after buying an additional 13,000 shares during the period. Lingohr & Partner Asset Management GmbH raised its position in shares of Gilead Sciences by 20.5% in the second quarter. Lingohr & Partner Asset Management GmbH now owns 12,347 shares of the biopharmaceutical company’s stock valued at $1,030,000 after buying an additional 2,100 shares during the period. Meyer Handelman Co. raised its position in shares of Gilead Sciences by 2.6% in the second quarter. Meyer Handelman Co. now owns 360,100 shares of the biopharmaceutical company’s stock valued at $30,039,000 after buying an additional 9,000 shares during the period. Finally, Checchi Capital Advisers LLC raised its position in shares of Gilead Sciences by 0.7% in the second quarter. Checchi Capital Advisers LLC now owns 13,978 shares of the biopharmaceutical company’s stock valued at $1,166,000 after buying an additional 102 shares during the period. 73.43% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.